The current proposal proposes to capitalize on our discoveries and to move forward in two
directions. First, pursue the protein/gene replacement approach until it produces a preclinical proof of
concept that includes a translatable delivery method. Second, assess the therapeutic potential of HDAC
inhibitors for ARSACS. Although not included as a specific aim in this proposal, developments with
HSP inducers in the ALS study will be applied in the ARSACS models.
Duration: One year
Grant: $80,000
Contacts
DR. Benoit Gentil
Room 649, Montreal Neurological Institute
3801 University street, Montreal, H3A 2B4
Tel: 514-398-8509; Fax: 514-398-1509; email: benoit.gentil@mcgill.ca
Dr. Heather Durham
Room 649, Montreal Neurological Institute
3801 University street, Montreal, H3A 2B4
Tel: 514-398-8509; Fax: 514-398-1509; email: heather.durham@mcgill.ca